labetalol has been researched along with Bradyarrhythmia in 13 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the efficacy of the combination of enalaprilat/labetalol with that of enalaprilat/nicardipine to prevent emergence postcraniotomy hypertension." | 9.09 | A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. ( Broad, C; Ferri, E; Kross, RA; Leung, D; Melendez, JA; Pratila, M; Veronesi, M, 2000) |
| "To assess the safety and efficacy of continuous infusion (CIV)-labetalol compared to -nicardipine in controlling blood pressure (BP) in the acute stroke setting." | 8.02 | Blood Pressure Control in Acute Stroke: Labetalol or Nicardipine? ( El-Ghoroury, H; Hecht, JP; Sudekum, DM, 2021) |
| "The episode of profound hypotension which occurred after initiating a labetolol infusion required maximal combined vasopressor therapy to restore the blood pressure suggesting that this patient demonstrated an extreme sensitivity to labetalol." | 7.73 | Case report: profound hypotension associated with labetalol therapy in a patient with cerebral aneurysms and subarachnoid hemorrhage. ( Baker, AJ; Choi, M; Hare, GM; Jivraj, S; Mazer, CD, 2006) |
| "It was discovered that labetalol withdrawal effects initially cause various degrees of hypotension, hypoglycemia, and bradycardia among exposed neonates." | 5.12 | Distinct outcomes of labetalol exposed infants: case reports and systematic review. ( Hui, L; Long, H; Yang, X; Zou, L, 2021) |
| "We compared the efficacy of the combination of enalaprilat/labetalol with that of enalaprilat/nicardipine to prevent emergence postcraniotomy hypertension." | 5.09 | A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. ( Broad, C; Ferri, E; Kross, RA; Leung, D; Melendez, JA; Pratila, M; Veronesi, M, 2000) |
| "To assess the safety and efficacy of continuous infusion (CIV)-labetalol compared to -nicardipine in controlling blood pressure (BP) in the acute stroke setting." | 4.02 | Blood Pressure Control in Acute Stroke: Labetalol or Nicardipine? ( El-Ghoroury, H; Hecht, JP; Sudekum, DM, 2021) |
| " labetalol hydrochloride with doses greater than 300 mg in 24 hours observed a high rate of bradycardia and hypotension, but the study found that these events rarely caused clinically significant hemodynamic compromise and was not statistically associated with adverse events." | 3.91 | Safety of high-dose intravenous labetalol in hypertensive crisis. ( Brandt, MM; Hecht, JP; Mahmood, SM, 2019) |
| "Our findings suggest that neonates born to mothers exposed to β blockers in late pregnancy, including labetalol, are at elevated risk for neonatal hypoglycemia and bradycardia." | 3.83 | Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. ( Bateman, BT; Desai, RJ; Fischer, MA; Hernandez-Diaz, S; Huybrechts, KF; Maeda, A; Mogun, H; Patorno, E; Seely, EW, 2016) |
| "The episode of profound hypotension which occurred after initiating a labetolol infusion required maximal combined vasopressor therapy to restore the blood pressure suggesting that this patient demonstrated an extreme sensitivity to labetalol." | 3.73 | Case report: profound hypotension associated with labetalol therapy in a patient with cerebral aneurysms and subarachnoid hemorrhage. ( Baker, AJ; Choi, M; Hare, GM; Jivraj, S; Mazer, CD, 2006) |
| "A single 30 mg intravenous dose of labetalol given 20 minutes prior to cesarean delivery at 35 weeks of gestation for severe pregnancy-induced hypertension was associated with symptoms of beta-adrenergic blockade (hypoglycemia, bradycardia, hypotension) in preterm twins." | 3.69 | Neonatal adrenergic blockade following single dose maternal labetalol administration. ( Bhatt-Mehta, V; Donn, SM; Klarr, JM, 1994) |
| " Safety was assessed according to adverse events that occurred during labetalol administration." | 1.91 | Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients. ( Duangprasert, G; Durongkaweroj, P; Noiphithak, R; Sukhor, S; Yindeedej, V, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Noiphithak, R | 1 |
| Duangprasert, G | 1 |
| Sukhor, S | 1 |
| Durongkaweroj, P | 1 |
| Yindeedej, V | 1 |
| Yang, X | 1 |
| Hui, L | 1 |
| Long, H | 1 |
| Zou, L | 1 |
| El-Ghoroury, H | 1 |
| Sudekum, DM | 1 |
| Hecht, JP | 2 |
| Singla, D | 1 |
| Parashar, A | 1 |
| Pandey, V | 1 |
| Mangla, M | 1 |
| Mahmood, SM | 1 |
| Brandt, MM | 1 |
| Bateman, BT | 1 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Seely, EW | 1 |
| Mogun, H | 1 |
| Maeda, A | 1 |
| Fischer, MA | 1 |
| Hernandez-Diaz, S | 1 |
| Huybrechts, KF | 1 |
| Jivraj, S | 1 |
| Mazer, CD | 1 |
| Baker, AJ | 1 |
| Choi, M | 1 |
| Hare, GM | 1 |
| Klarr, JM | 1 |
| Bhatt-Mehta, V | 1 |
| Donn, SM | 1 |
| Dannon, PN | 1 |
| Iancu, I | 1 |
| Hirschmann, S | 1 |
| Ross, P | 1 |
| Dolberg, OT | 1 |
| Grunhaus, L | 1 |
| Huang, YC | 1 |
| Wu, BN | 1 |
| Lin, YT | 1 |
| Chen, SJ | 1 |
| Chiu, CC | 1 |
| Cheng, CJ | 1 |
| Chen, IJ | 1 |
| Pittman, JA | 1 |
| Kross, RA | 1 |
| Ferri, E | 1 |
| Leung, D | 1 |
| Pratila, M | 1 |
| Broad, C | 1 |
| Veronesi, M | 1 |
| Melendez, JA | 1 |
| Flamenbaum, W | 1 |
| Weber, MA | 1 |
| McMahon, FG | 1 |
| Materson, BJ | 1 |
| Carr, AA | 1 |
| Poland, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficiency of Intravenous Lidocaine to Reduce Coughing and the Hemodynamic Changes Associated to Tracheal Extubation[NCT03731429] | Phase 4 | 144 participants (Anticipated) | Interventional | 2019-04-05 | Recruiting | ||
| Nicardipine Versus Esmolol for Management of Emergence Hypertension After Craniotomy[NCT01951950] | Phase 1 | 40 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01951950)
Timeframe: 1 hour postoperatively
| Intervention | participants (Number) |
|---|---|
| Nicardipine | 1 |
| Esmolol | 11 |
1 review available for labetalol and Bradyarrhythmia
| Article | Year |
|---|---|
Distinct outcomes of labetalol exposed infants: case reports and systematic review.
Topics: Bradycardia; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Labetalol; Maternal Exposur | 2021 |
4 trials available for labetalol and Bradyarrhythmia
| Article | Year |
|---|---|
Comparative evaluation of dexmedetomidine and labetalol for attenuating hemodynamic stress responses during laparoscopic cholecystectomy in borderline hypertensive patients.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Blood Pressure; Bradycardia; Cholecystectomy, Laparosco | 2019 |
Labetalol does not lengthen asystole during electroconvulsive therapy.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Adult; Aged; Blood Pressure; Bradycardia; Combi | 1998 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
Monotherapy with labetalol compared with propranolol. Differential effects by race.
Topics: Adult; Aged; Black or African American; Bradycardia; Clinical Trials as Topic; Dizziness; Double-Bli | 1985 |
8 other studies available for labetalol and Bradyarrhythmia
| Article | Year |
|---|---|
Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients.
Topics: Blood Pressure; Bradycardia; Humans; Hypotension; Labetalol; Retrospective Studies | 2023 |
Blood Pressure Control in Acute Stroke: Labetalol or Nicardipine?
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pre | 2021 |
Safety of high-dose intravenous labetalol in hypertensive crisis.
Topics: Administration, Intravenous; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bradycardia; Dose | 2019 |
Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia.
Topics: Adrenergic beta-Antagonists; Atenolol; Bradycardia; Cohort Studies; Female; Humans; Hypertension; Hy | 2016 |
Case report: profound hypotension associated with labetalol therapy in a patient with cerebral aneurysms and subarachnoid hemorrhage.
Topics: Antihypertensive Agents; Bradycardia; Cardiotonic Agents; Dopamine; Epinephrine; Female; Humans; Hyp | 2006 |
Neonatal adrenergic blockade following single dose maternal labetalol administration.
Topics: Adult; Bradycardia; Diseases in Twins; Female; Fetal Blood; Humans; Hypoglycemia; Hypotension; Infan | 1994 |
Eugenodilol: a third-generation beta-adrenoceptor blocker, derived from eugenol, with alpha-adrenoceptor blocking and beta2-adrenoceptor agonist-associated vasorelaxant activities.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Anesthesia; Animals; Aorta, Thoracic; Bradyca | 1999 |
Magnesium sulphate for pre-eclampsia and a sudden bradycardia.
Topics: Adolescent; Adrenergic beta-Antagonists; Bradycardia; Calcium Channel Blockers; Drug Interactions; F | 2000 |